Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest EU patient information plan includes fresh drug safety measures

This article was originally published in SRA

Executive Summary

The latest draft of the European Commission's proposed legislation on patient information will allow pharmaceutical companies to provide information on their prescription drugs to the public, but only in a very circumscribed manner. It will also place an obligation on them to make certain information available, such as the product's labelling and pack leaflet.

You may also be interested in...



Russia’s Sputnik V COVID-19 Vaccine Starts EU Rolling Review

The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.

Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval

Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.

Slovakia Becomes Second EU Country To OK Use Of Russian Vaccine

While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel